Horse Osteoprotegerin ELISA Kit | MyBioSource MBS018149 product information

product summary

company name :

MyBioSource

product type :

ELISA/assay

product name :

Horse Osteoprotegerin ELISA Kit

catalog :

MBS018149

quantity :

48-Strip-Wells

price :

435 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS018149

products type :

ELISA Kit

products full name :

Horse Osteoprotegerin ELISA Kit

products short name :

Osteoprotegerin

other names :

osteoprotegerin; Tumor necrosis factor receptor superfamily member 11B; tumor necrosis factor receptor superfamily member 11B; osteoprotegerin; osteoclastogenesis inhibitory factor; tumor necrosis factor receptor superfamily, member 11b; Osteoclastogenesis inhibitory factor; Osteoprotegerin

products gene name :

OPG

other gene names :

TNFRSF11B; TNFRSF11B; OPG; TR1; OCIF; OCIF; OPG

uniprot entry name :

TR11B_HUMAN

reactivity :

Horse

specificity :

No significant cross-reactivity or interference between this analyte and analogues is observed.

storage stability :

Store all reagents at 2-8 degree C

other info1 :

Samples: Undiluted original Horse body fluids, tissue homogenates, secretions or feces samples. This kit is NOT suitable for assaying non-biological sources of substances. Assay Type: Sandwich. Detection Range: 0.5 ng/ml - 16 ng/ml. Sensitivity: 0.1 ng/ml.

other info2 :

Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100].

products description :

Background/Introduction: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! This kit is intended to be used for determination the level of OPG (hereafter termed "analyte") in undiluted original Horse body fluids, tissue homogenates, secretions or feces samples. This kit is NOT suitable for assaying non-biological sources of substances.

ncbi gi num :

2072185

ncbi acc num :

AAB53709.1

uniprot acc num :

O00300

ncbi mol weight :

46,026 Da

ncbi pathways :

Apoptosis Modulation And Signaling Pathway (198822); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Monoamine Transport Pathway (198851); Osteoblast Signaling Pathway (198842); Osteoclast Signaling Pathway (198769); Osteoclast Differentiation Pathway (193147); Osteoclast Differentiation Pathway (193096); RANKL/RANK Signaling Pathway (672447)

ncbi summary :

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

uniprot summary :

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal. Protein type: Secreted; Secreted, signal peptide; Inhibitor. Chromosomal Location of Human Ortholog: 8q24. Cellular Component: proteinaceous extracellular matrix; extracellular space; extracellular region. Molecular Function: cytokine activity; receptor activity. Biological Process: response to drug; extracellular matrix organization and biogenesis; response to magnesium ion; response to estrogen stimulus; negative regulation of odontogenesis of dentine-containing teeth; apoptosis; response to arsenic; negative regulation of bone resorption; signal transduction; skeletal development; response to nutrient. Disease: Paget Disease, Juvenile

size1 :

48-Strip-Wells

price1 :

435 USD

size2 :

96-Strip-Wells

price2 :

600

more info or order :

MyBioSource product webpage